Tango and Erasca’s Phase I/II trial of ERAS-0015 combo opens for enrolment

The multi-centre, open-label study is sponsored by Tango Therapeutics and consists of dose-escalation and expansion phases.
MarketScreener

Coya to Initiate Open-Label Extension of Phase 2/3 ALSTARS Trial of COYA 302 in ALS

Coya is currently conducting the ALSTARS Trial, a Phase 2/3, randomized, multi-center, double-blind, placebo-controlled study to evaluate the efficacy and safety of COYA 302 for the treatment of ALS ...
Nasdaq

Satellos Announces Encouraging Functional Data from the 28-day Phase 1b Open-Label Trial of SAT-3247 in Adults with Duchenne Muscular Dystrophy

Phase 1b data shows treatment with SAT-3247 was safe and well-tolerated Pharmacokinetic (PK) profile of SAT-3247 translated as expected to Duchenne Muscular Dystrophy (DMD) patients taking concurrent ...
Geelong Advertiser

The quiet catalyst: Why open-label extension trials matter for ASX biotechs

Open-label extension trials provide long-term follow-up after a main trial is completed and are a key part of drug development DXB is undertaking an open-label extension study following its pivotal ...
The Manila Times

Sagimet To Present Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne and Mechanistic Data at the ...

Denifanstat showed continued improvement and sustained efficacy across all efficacy endpoints through 52 weeks, including 57% IGA success, 72% reduction in total lesions, and 77% reduction in ...